nizatidine (axid) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Nizatidine, chemically N-[2-[[[2- [(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N’ -methyl-2-nitro-1,1-ethenediamine, is a histamine H2-receptor antagonist. Nizatidine reduced gastric acid secretion for up to 8 h suggesting that this compound could be used in with a once or twice daily dosage regime. Nizatidine was rapidly and well-absorbed orally, was widely distributed in tissues and the majority of the dose was excreted in the urine within 24 h. Nizatidine is indicated for duodenal and gastric ulcer as well as for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gastroesophageal reflux disease.   NCATS

Chemistry

  • SMILES: CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
  • InChIKey: SGXXNSQHWDMGGP-UHFFFAOYSA-N
  • Mol. Mass: 331.47
  • ALogP: 1.32
  • ChEMBL Molecules:
    nizatidine  
    None  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.1349 - $0.4406

United States

$0.3631 - $1.0084
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

axid | axid ar | ly-139037 | naxidine | nizatidina | nizatidine | nizatidinum | nizaxid | zinga 150 | zinga 300

Organizations (24)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (3)


 

Duodenal Ulcer (approved 2011)

Gastroesophageal Reflux (approved 2011)

Peptic Ulcer (approved 2011)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Gastritis (Phase 4)

Gastroesophageal Reflux (Phase 3)

Gastroparesis (Phase 1)

Healthy Volunteers (Phase 1)

Heartburn (Phase 3)

Respiratory Aspiration (Phase 4)

Schizophrenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue